Related Experiment Video
Updated: Nov 10, 2025
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Diabetes and COVID-19
1Department of Internal Medicine, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah 21577, Saudi Arabia.
Insights
Individuals with diabetes or hyperglycemia face significantly higher mortality risks from Coronavirus disease-19 (COVID-19). Managing blood sugar is crucial for improving outcomes in these patients.
Area of Science:
- Internal Medicine
- Infectious Diseases
- Endocrinology
Background:
- Coronavirus disease-19 (COVID-19) presents increased mortality risks associated with several comorbidities.
- Hyperglycemia and diabetes mellitus are significant risk factors, leading to severe COVID-19 complications, higher ICU admission rates, and increased mortality.
Purpose of the Study:
- To investigate the impact of hyperglycemia and diabetes on COVID-19 severity and mortality.
- To highlight the mechanisms by which elevated blood sugar levels exacerbate viral infections.
- To emphasize the need for integrated care strategies for diabetic patients with COVID-19.
Main Methods:
- Literature review and analysis of existing studies on COVID-19 and diabetes.
- Examination of clinical data linking hyperglycemia to COVID-19 outcomes.
- Analysis of immunological and molecular mechanisms affected by high blood glucose.
Main Results:
- Patients with diabetes or hyperglycemia exhibit a two- to four-fold increase in COVID-19 mortality and severity.
- Hyperglycemia impairs immune response, affecting bacterial degradation, neutrophil function, and viral clearance.
- Glycosylation induced by high blood sugar levels increases cellular susceptibility to viral inflammation and damage.
Conclusions:
- Effective management of COVID-19 in diabetic patients requires a multidisciplinary team approach.
- Proactive strategies focusing on comorbidities are essential to reduce complications and mortality.
- Integrated care can alleviate the burden on healthcare systems by improving patient outcomes.
Abstract:
Several factors are linked with a higher risk of mortality from Coronavirus disease-19 (COVID-19), including male gender, increased age, hypertension, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, and cancer. Hyperglycemic COVID-19 patients have severe clinical problems, increased ICU admittance, machine-driven ventilation, and a substantial rise in inflammatory markers. Among all patients, those with diabetes or hyperglycemia have a two- to four-fold increase in mortality and severity of COVID-19 than those without diabetes. The primary cause of mortality in COVID-19 patients with diabetes is compromised immune response to viral infections. Increased blood sugar level probably affects intracellular degradation of bacteria, neutrophil chemotaxis, and phagocytosis, thus improving viral binding affinity and entry and decreasing virus clearance. In addition, it has significant effects on the proteins by inducing glycosylation and altering the composition of complements, and glycosylation renders cells susceptible to viral inflammation and damage. The treatment of COVID-19 in patients with diabetes requires an integrated team approach to minimize the risk of medical complications and mortality. Moreover, physicians should adopt proactive strategies to care for persons with comorbidities. This strategy would help reduce the frequency of complications and mortality among patients and load on the healthcare system.
Related Concept Videos
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:15Diabetes: Symptoms, Diagnosis, and Complications
01:22Diabetes Mellitus: Type 2 and Gestational
01:19Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
01:19Psychoneuroimmunology: Diabetes and Cancer
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...